SCHEMBL5307253

SCHEMBL5307253

O=C(NC(=O)c1ccccc1O)c1ccc(C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 1.00
RAB9A P51151 6/20 1.00
CRHBP P24387 1/20 1.00
CRHR2 Q13324 1/20 1.00
KMT2A Q03164 6/20 0.58
POLB P06746 1/20 0.58
MCOLN3 Q8TDD5 1/20 0.58
CTDSP1 Q9GZU7 1/20 0.58
P2RX1 P51575 2/20 0.57
P2RX4 Q99571 1/20 0.57
P2RX7 Q99572 1/20 0.57
ALPL P05186 1/20 0.52
ALPI P09923 1/20 0.52
ALPG P10696 1/20 0.52
NLRP3 Q96P20 1/20 0.52
KDM4E B2RXH2 3/20 0.50
MEN1 O00255 3/20 0.50
HTT P42858 2/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP2D6 P10635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9609341 0.85 NPC1 (0.74) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL19032011 0.83 NPC1 (0.70) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL2698258 0.81 P2RX1 (0.75) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL30665186 0.81 P2RX1 (0.75) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL70688 0.80 KDM4E (0.71) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL12829081 0.80 NPC1 (0.76) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL15372514 0.80 KMT2A (0.71) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL685110 0.80 KDM1A (0.75) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL17787595 0.79 NPC1 (0.66) NPC1RAB9ACRHBPCRHR2KMT2A
SCHEMBL18341280 0.79 TMPRSS4 (0.71) NPC1RAB9ACRHBPCRHR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070148185-A1 Novel therapeutic target for protozoal diseases VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY 2007-06-28 US claimed
WO-2007047579-A2 A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2007-04-26 WO claimed
US-8957140-B2 Triazine derivative, ultraviolet absorber, and resin composition FUJIFILM CORPORATION (JP) 2015-02-17 US disclosed
US-8748520-B2 Polycarbonate resin composition containing triazine compound and molded article using the same FUJIFILM CORPORATION (JP) 2014-06-10 US disclosed
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-05-31 US disclosed
US-20110077331-A1 POLYCARBONATE RESIN COMPOSITION CONTAINING TRIAZINE COMPOUND AND MOLDED ARTICLE USING THE SAME FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed
EP-2301995-A1 Polycarbonate resin composition containing triazine compound and molded article using the same Fujifilm Corporation (JP) 2011-03-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION C1R, RPSA, H1-2 NPC1 4182/4885RAB9A 2727/4885CRHBP 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.